Article
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Pharmacogenetics and genomics - 1 Aug 2023
Agyemang Nana, Scarsi Kimberly K, Baker Paxton, Smeaton Laura M, Podany Anthony T, Olefsky Maxine, Woolley Elizabeth, Barr Elizabeth, Pham Michelle, Mawlana Sajeeda, Supparatpinyo Khuanchai, Gatechompol Sivaporn, Jalil Emilia M, Gadama Luis, Badal-Faesen Sharlaa, Van Schalkwyk Marije, Kayama Cecelia, Belaunzaran-Zamudio Pablo F, Godfrey Catherine, Cohn Susan E, Mngqibisa Rosie, Haas David W
Abstract excerpt
OBJECTIVE: In AIDS Clinical Trials Group study A5375, a pharmacokinetic trial of levonorgestrel emergency contraception, double-dose levonorgestrel (3 mg, versus standard dose 1.5 mg) offset the induction effects of efavirenz or rifampin on plasma levonorgestrel exposure over 8 h post-dose (AUC 0-8h ). We characterized the pharmacogenetics of these interactions. METHODS: Cisgender women receiving efavirenz- or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
